Literature DB >> 11464895

Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.

J M Maris1, C Guo, P S White, M D Hogarty, P M Thompson, D O Stram, R Gerbing, K K Matthay, R C Seeger, G M Brodeur.   

Abstract

BACKGROUND: Neuroblastoma tumorigenesis may involve the differential inactivation of multiple tumor suppressor genes. Recent data have suggested that a neuroblastoma suppressor gene may be located on the long arm of chromosome 11 (11q). PROCEDURE: We therefore analyzed 295 primary neuroblastomas from a representative group of patients for loss of heterozygosity (LOH) at 25 polymorphic markers spanning 11q.
RESULTS: LOH was observed in 129 primary neuroblastomas (44%), and a common region of LOH mapped to 11q14-23. No correlation was found between 11q LOH and adverse prognostic variables, but a strong inverse relationship between 11q LOH and MYCN amplification (P < 0.001) was observed. There was no difference in overall survival when patients were stratified by 11q LOH status. However, 11q LOH was associated with a decreased overall survival probability when patients whose tumors had a single copy of MYCN were analyzed separately (P = 0.008).
CONCLUSION: These data support the hypothesis that a tumor suppressor gene mapping within 11q14-23 is frequently inactivated during the malignant evolution of neuroblastoma.

Entities:  

Mesh:

Year:  2001        PMID: 11464895     DOI: 10.1002/1096-911X(20010101)36:1<24::AID-MPO1007>3.0.CO;2-7

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  19 in total

1.  Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.

Authors:  Masato Kojima; Eiso Hiyama; Ikuko Fukuba; Emi Yamaoka; Yuka Ueda; Yoshiyuki Onitake; Shou Kurihara; Taijiro Sueda
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

2.  The transcription factor CREBZF is a novel positive regulator of p53.

Authors:  Irene López-Mateo; M Ángeles Villaronga; Susana Llanos; Borja Belandia
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

Review 3.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

4.  Molecular characterization of the pediatric preclinical testing panel.

Authors:  Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; C Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey Dome; Joseph Khoury; Timothy J Triche; Robert C Seeger; Richard Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

5.  Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

Authors:  Wayne H Liang; Sara M Federico; Wendy B London; Arlene Naranjo; Meredith S Irwin; Samuel L Volchenboum; Susan L Cohn
Journal:  JCO Clin Cancer Inform       Date:  2020-10

Review 6.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Bioinformatics analysis of recurrent deletion regions in neuroblastoma.

Authors:  Hasan Onur Caglar
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

8.  Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes.

Authors:  Katleen De Preter; Jo Vandesompele; Pierre Heimann; Nurten Yigit; Siv Beckman; Alexander Schramm; Angelika Eggert; Raymond L Stallings; Yves Benoit; Marleen Renard; Anne De Paepe; Geneviève Laureys; Sven Påhlman; Frank Speleman
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

Review 9.  Acceleration or Brakes: Which Is Rational for Cell Cycle-Targeting Neuroblastoma Therapy?

Authors:  Kiyohiro Ando; Akira Nakagawara
Journal:  Biomolecules       Date:  2021-05-18

10.  No evidence for involvement of SDHD in neuroblastoma pathogenesis.

Authors:  Katleen De Preter; Jo Vandesompele; Jasmien Hoebeeck; Caroline Vandenbroecke; Jöel Smet; Annick Nuyts; Geneviève Laureys; Valérie Combaret; Nadine Van Roy; Frank Roels; Rudy Van Coster; Marleen Praet; Anne De Paepe; Frank Speleman
Journal:  BMC Cancer       Date:  2004-08-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.